ULTRA-DILUTED VISCUM ALBUM IN THE TREATMENT OF CUTANEOUS MELANOMA IN A DOG (CANIS FAMILIARIS) - CASE REPORT

Background: Cutaneous melanoma is one of the tumors with the highest incidence in middle-aged dogs. Effective systemic treatments for advanced malignant melanoma are lacking, and survival is about 1 to 3 months. Viscum album therapy is among the complementary therapies against cancer. A 7-year-old Dogue de Bordeaux female d Methods: og. The main complaint was an ulcerated lesion in the right anterior leg. The animal had already been diagnosed with malignant cutaneous melanoma 11 months before. Extensive ulcerated lesions in the fourth digit of the right anterior leg, mandibular region, and labial commissures were observed for more than nine months, with no resolution of the initial condition. Pulmonary metastasis in the left caudal lobe, two evolving breast tumors, and several blackish nodular lesions spread through the abdomen, lower eyelids, and auricular pavilions were already diagnosed. An injectable, -3 homeopathic treatment was prescribed and consisted of an intravenous application of Viscum album D3 (1x10 ) and -3 -6 auto-hemotherapy, once a week. At home, the tutor performed applications of Viscum album D3 (1x10 ), D6 (1x10 ), D12 -12 -30 (1x10 ), D30 (1x10 ), in combinations, SID, subcutaneously, three times a week. The protocol administ Conclusion: ered to the patient in this study was successful in its purpose. It healed the wounds and improved the patient's quality of life. Other studies must be conducted, under the same conditions, to better elucidate the results obtained in the present study.

RAGE Signaling in Melanoma Tumors

Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.

Jejunojejunal intussusception secondary to metastatic uveal melanoma after 11 years of remission

Malignant cutaneous melanoma frequently metastasises to gastrointestinal tract, small bowel being the most common site likely due to its rich vascular supply. However, most common sites for metastatic uveal melanoma are the liver (93%), lung (24%), bone (16%), skin/subcutaneous tissue (11%) and lymph nodes (10%). 1 We present a case of 46-year-old man with jejunojejunal intussusception secondary to metastatic uveal melanoma status postbrachytherapy after 11 years of remission. We aim to highlight the rare occurrence of adult intussusception secondary to uveal melanoma after a prolonged period of remission.